EXHIBIT 10.24
AMENDMENT No. 11
to
THE DEVELOPMENT AND MANUFACTURING
SERVICES AGREEMENT
Dated 08 January 2004
Between
LONZA BIOLOGICS PLC
and
TRUBION PHARMACEUTICALS, INC.
CONFIDENTIAL TREATMENT
THIS AMENDMENT No. 11 ("Eleventh Amendment") is made the 31st day of March 2006
BETWEEN
LONZA BIOLOGICS PLC of 000 Xxxx Xxxx, Xxxxxx, Xxxxxxxxx XX0 0XX, Xxxxxxx
(hereinafter referred to as "LB"), and
TRUBION PHARMACEUTICALS, INC., of 0000 0xx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX
00000, XXX (herein after referred to as the "Customer")
WHEREAS
A. LB and the Customer entered into a development and manufacturing services
agreement ("the Agreement") dated 08 January 2004, pursuant to which LB
agreed to provide Services to the Customer, and,
B. The Customer now wishes LB to perform additional services under the
Agreement, and,
C. LB is willing to perform such additional services on the terms set out in
the Agreement, and,
D. The parties wish to amend the Agreement in accordance with Clause 13.5
thereto.
NOW THEREFORE IT IS HEREBY AGREED as follows:
1. SCHEDULE 1 OF THE AGREEMENT SHALL BE AMENDED TO INCLUDE THE FOLLOWING:
(a) ***
***.
TEST METHOD
NO. CRITERION (LB SOP NUMBER) SPECIFICATION
---- --------- --------------- -------------
Characteristics
*** *** *** ***
*** *** *** ***
*** *** *** ***
*** *** *** ***
*** *** *** ***
TEST METHOD
NO. CRITERION (LB SOP NUMBER) SPECIFICATION
---- --------- --------------- -------------
Identity
*** *** *** ***
CONFIDENTIAL TREATMENT
***
*** *** *** ***
*** *** *** ***
TEST METHOD
NO. CRITERION (LB SOP NUMBER) SPECIFICATION
---- --------- --------------- -------------
Impurities
*** *** *** ***
*** *** *** ***
*** *** *** ***
***
*** *** *** ***
*** *** *** ***
TEST METHOD
NO. CRITERION (LB SOP NUMBER) SPECIFICATION
---- --------- --------------- -------------
Safety
*** *** *** ***
*** *** *** ***
Storage and shipping information
Final Formulation Buffer: *** (Pharmaceutical Grade)
Bottling of Bulk Product:
Primary containers: ***
Denominations:
***
Product Storage Conditions: ***.
Shipment Temperature: ***.
CONFIDENTIAL TREATMENT
-2-
Customer samples (removed during the middle of dispensing):
To be agreed by LB and Customer.
Shipment Temperature: ***.
2. SCHEDULE 2 OF THE AGREEMENT SHALL BE AMENDED TO AMEND STAGE 27 AND ADD
STAGES 34 AND 35 TO READ AS FOLLOWS:
"27 STAGE 27 ***
BACKGROUND
***
27.1 OBJECTIVES
***
27.2 ACTIVITIES
***
27.3 TIMESCALE
This stage may commence upon receipt of the subsequent Cell Line
at LB and it is estimated that this stage shall be complete
approximately *** from commencement of the stage.
34. STAGE 34 ***
BACKGROUND
***
34.1 OBJECTIVES
***
34.2 ACTIVITIES
***
34.3 TIMESCALE
This Stage can commence as soon as the relevant information is
received from the Customer. This Stage shall be an ongoing
process but will be set as to not be a rate-limiting step.
CONFIDENTIAL TREATMENT
-3-
It is estimated that this Stage shall be complete *** from the
commencement of this Stage.
Note: Following activity 34.2.6, any additional work above and
beyond the scope identified in Stage 34 herein would be
subject to agreement by both parties and would be carried
out under terms and conditions to be agreed.
35 STAGE 35 ***
BACKGROUND
***
35.1 OBJECTIVES
***
35.2 ACTIVITIES
***
35.3 TIMESCALE
This Stage may commence when:
- the *** of the Customer Cell Lines are available and
approved by LB for use, and
- sufficient information is available for the Services to
proceed.
This Stage shall be complete upon issue of the summary report to
the Customer. It is estimated that this report shall be issued
*** from commencement of this Stage.
CONFIDENTIAL TREATMENT
-4-
SCHEDULE 3 TO THE AGREEMENT SHALL BE AMENDED TO INCLUDE PROVISION FOR PAYMENT
FOR THE ABOVE MENTIONED ADDITIONAL SERVICES, AS SET OUT BELOW HERETO. INVOICES
FOR THESE ADDITIONAL SERVICES SHALL BE ISSUED, AND CUSTOMER PAYMENTS SHALL BE
MADE, ***:
"1. Price
***
2. Payment
FOR STAGE 27
*** upon commencement of Stage 27.
*** upon completion of Stage 27.
FOR STAGE 34
*** upon commencement of Stage 34.
*** upon completion of Stage 34
FOR STAGE 35
*** upon commencement of Stage 35.
*** upon completion of Stage 35
***
CONFIDENTIAL TREATMENT
-5-
LONZA
SAVE AS HEREIN PROVIDED ALL OTHER TERMS AND CONDITIONS OF THE AGREEMENT SHALL
REMAIN IN FULL FORCE AND EFFECT.
AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.
Signed for and on behalf of
LONZA BIOLOGICS PLC /s/ Xxx Xxxxxx
----------------------------------------
VP Global Biologics Quality
TITLE
Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC /s/ Xxxxxxx X. Xxxxxx
----------------------------------------
Senior VP, Research & Development
TITLE
CONFIDENTIAL TREATMENT
